R
Raphaele Nove-Josserand
Researcher at University of Lyon
Publications - 41
Citations - 880
Raphaele Nove-Josserand is an academic researcher from University of Lyon. The author has contributed to research in topics: Cystic fibrosis & Population. The author has an hindex of 15, co-authored 35 publications receiving 725 citations. Previous affiliations of Raphaele Nove-Josserand include Necker-Enfants Malades Hospital.
Papers
More filters
Journal ArticleDOI
Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect.
Marion Malphettes,Laurence Gérard,Maryvonnick Carmagnat,Gael Mouillot,Nicolas Vince,David Boutboul,Alice Bérezné,Raphaele Nove-Josserand,Vincent Lemoing,L. Tetu,Jean-François Viallard,Bernard Bonnotte,Michel Pavic,Julien Haroche,Claire Larroche,Jean-Claude Brouet,Jean-Paul Fermand,Claire Rabian,Claire Fieschi,Eric Oksenhendler +19 more
TL;DR: Identification of systematic T cell phenotype should result in a more fitted diagnostic and therapeutic approach of infections and could provide insights for genetic diagnosis.
Journal ArticleDOI
The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening
Christel Thauvin-Robinet,Anne Munck,F. Huet,Emmanuelle Génin,G. Bellis,Elodie Gautier,Marie-Pierre Audrézet,Claude Férec,Guy Lalau,Georges,Mireille Claustres,T Bienvenu,Bénédicte Gérard,Pierre Boisseau,Cabet-Bey F,Delphine Feldmann,Christine Clavel,Eric Bieth,A Iron,Brigitte Simon-Bouy,Catherine Costa,R. Medina,J. Leclerc,Dominique Hubert,Raphaele Nove-Josserand,Isabelle Sermet-Gaudelus,Gilles Rault,J. Flori,Sylvie Leroy,N. Wizla,Gabriel Bellon,A. Haloun,S. Perez-Martin,d'Acremont G,Harriet Corvol,Annick Clement,E. Houssin,Christine Binquet,Claire Bonithon-Kopp,C. Alberti-Boulmé,Michael A. Morris,Laurence Faivre,Michel Goossens,M Roussey,Emmanuelle Girodon +44 more
TL;DR: It is suggested that R117H should be withdrawn from CF mutation panels used for screening programmes and the real impact of so-called disease mutations should be assessed before including them in newborn or preconceptional carrier screening programmes.
Journal ArticleDOI
Pharmacokinetics and safety of tobramycin administered by the PARI eFlow® rapid nebulizer in cystic fibrosis
Dominique Hubert,Sylvie Leroy,Raphaele Nove-Josserand,Marlène Murris-Espin,Laurent Mely,Stephane Dominique,B. Delaisi,Pearl Kho,John M. Kovarik +8 more
TL;DR: Use of the eFlow rapid nebulizer reduced TSI nebulization time and the systemic exposure to tobramycin appeared to be broadly similar in this exploratory study.
Journal ArticleDOI
Sleep quality and nocturnal hypoxaemia and hypercapnia in children and young adults with cystic fibrosis
Brigitte Fauroux,Jean-Louis Pépin,Pierre-Yves Boëlle,Claire Cracowski,Marlène Murris-Espin,Raphaele Nove-Josserand,Nathalie Stremler,Tabassome Simon,Pierre-Régis Burgel +8 more
TL;DR: Patients with CF exhibit poor sleep quality that does not predict nocturnal gas exchange, and Nocturnal hypoxaemia and hypercapnia can be identified by simple tools.
Journal ArticleDOI
Protective effect of IgM against colonization of the respiratory tract by nontypeable Haemophilus influenzae in patients with hypogammaglobulinemia.
Romain Micol,Romain Micol,Samer Kayal,Samer Kayal,Nizar Mahlaoui,Julien Beauté,Pauline Brosselin,Yasmine Dudoit,Gaelle Obenga,Vincent Barlogis,Nathalie Aladjidi,Kamila Kebaili,Caroline Thomas,Fabienne Dulieu,Fabrice Monpoux,Raphaele Nove-Josserand,Isabelle Pellier,Olivier Lambotte,Alexandra Salmon,Agathe Masseau,Pierre Galanaud,Eric Oksenhendler,Marie-Dominique Tabone,Pierre Teira,Hélène Coignard-Biehler,Fanny Lanternier,Olivier Join-Lambert,Olivier Join-Lambert,Gael Mouillot,Ioannis Theodorou,Jean-Claude Lecron,Marie-Alexandra Alyanakian,Marie-Alexandra Alyanakian,Capucine Picard,Stéphane Blanche,Stéphane Blanche,Olivier Hermine,Olivier Hermine,Felipe Suarez,Felipe Suarez,Marianne Debré,Marc Lecuit,Olivier Lortholary,Olivier Lortholary,Anne Durandy,Anne Durandy,Alain Fischer +46 more
TL;DR: In this paper, the authors identify specific microbiological and clinical characteristics that distinguish immunoglobulin-substituted patients with panhypogammaglobulinemia from patients with hyper-IgM [HIgM] syndrome.